Abstract Purpose: We recently found that adipose differentiation-related protein (ADFP) is a potential diagnostic and prognostic biomarker for clear cell subtype renal cell carcinoma (RCC). To further evaluate the correlation between ADFP expression levels and clinicopathologic characteristics and patient outcome, we retrospectively examined patients with clear cell RCC. Experimental Design: A series of 432 consecutive patients with sporadic clear cell RCC who underwent nephrectomy between March 1986 and June 2004 were enrolled in the study. ADFP expression levels in the primary tumors and in 18 metastases were measured by real-time quantitative PCR. The clinicopathologic and prognostic data were collected, as well as the von HippelLindau disease (VHL) gene alteration status in selected cases. Results: ADFP expression was apparently high in cases without a symptomatic presentation, as well as in cases of low-stage, low-grade, or VHL alteration^positive clear cell RCC, whereas it was down-regulated in undifferentiated tumors with a spindle/pleomorphic component or metastatic lesions. Univariate analyses showed that high ADFP expression was associated with better cancer-specific survival and cancer-free survival. Further Cox multivariate analyses combined with the split-sample validation method showed that ADFP expression still remains an independent predictor for cancer-specific survival in all tumor stages and in advanced metastatic cases, whereas the predictive value of ADFP expression for cancer recurrence is rather weak. Conclusions: The ADFP expression may represent the tumor differentiation status, and the detection of the expression levels provides useful prognostic information for cancer-specific survival in patients with clear cell RCC.
protein (ADFP) is highly up-regulated both at the transcriptional and protein levels in clear cell RCC cells (11) . ADFP is characterized as one of the crucial proteins involved in fatty acid uptake and in the formation and stabilization of lipid storage droplets (12, 13) . ADFP is expressed at high levels in adipocytes and is also expressed at various levels in many different types of cells, including lactating mammary epithelial cells, adrenal cortex cells, Sertoli and Leydig cells of the male reproductive system, and fatty change hepatocytes in alcoholic liver cirrhosis (14 -17) . Of interest, ADFP is characterized as one of the hypoxia-inducible genes, and its transcriptional activation is mediated by hypoxia-inducible factor (HIF; ref. 18) . It has been shown that HIF-a is the critical target for ubiquitin-dependent proteasome degradation by the VHLElonginBC-Cul2/Rbx ubiquitin ligase complex in clear cell RCC cells (4, 9, 10) . Collectively, these findings suggest that disruption of the VHL tumor suppressor/HIF pathway is likely involved in the up-regulation of ADFP in clear cell RCC (11) . Moreover, our preliminary data suggested that patients with tumors that showed a high level of ADFP expression had better survival rates than patients with tumors having a low level of ADFP expression (11) .
In the present study, to further elucidate the significance of ADFP as a molecular expression marker, we examined 432 consecutive patients with sporadic clear cell RCC. In selected cases, we also measured ADFP expression levels in the metastatic tumor tissues concomitant with the primary RCC and compared these expression levels. We used the Cox regression model combined with the split-sample method (i.e., a trainingtest approach) to validate the survival tests.
Materials and Methods
Patients with clear cell RCC. Primary tumors and corresponding normal kidney samples were collected from 432 consecutive patients with sporadic clear cell RCC who underwent nephrectomy between March 1986 and June 2004. Eighteen metastatic tumor lesions were also resected as a surgical treatment for selected patients. Advanced metastatic patients were basically treated by the standard protocols, mainly by IFN-a -and/or low-dose interleukin-2 -based immunotherapy. None of the patients received novel experimental therapies, such as allogeneic stem cell transplantation, tumor vaccines, or molecular targeted medicines (19, 20) . Fresh tumor materials without apparent necrosis were grossly resected, snap-frozen with liquid nitrogen, and stored at À80jC until nucleic acid extraction. The histopathology of the tumors was classified according to standard classifications (5, 6) . Tumor stage and grade were determined according to the tumor-nodemetastasis classification (21) . Among the 432 patients with clear cell RCC, 103 cases had already been examined in a previous report on the association of ADFP with clinicopathologic characteristics (11) . We newly studied the ADFP expressions in the remaining 329 cases. Of the 432 patients, presumably curative surgery was done in 339, including 329 Unio Internationale Contra Cancrum stage I to III patients who underwent nephrectomy (313 conventional and 16 partial nephrectomies) and 10 stage IV patients with metastases in a solitary organ who underwent radical nephrectomy together with curative surgical resection for the metastases. Cancer-free survival was therefore determined for this 339-patient cohort. The remaining 93 patients with stage IV disease received a palliative or adjunctive nephrectomy. All patients were followed up by urologists at intervals of 1 to 6 months. As of January 2006, when the follow-up ended, the follow-up times had ranged from 0.4 to 236.5 months and the median follow-up time after nephrectomy was 68.7 months for all patients and 84.5 months for survivors (Supplementary Table S1 ). The study protocol was approved by the institutional review board.
Measurement of ADFP expression by real-time quantitative PCR. Frozen tissue fragments without microdissection were mechanically disrupted in Isogen reagent (Nippon Gene, Tokyo, Japan) using a microtube homogenizer (Toyobo, Osaka, Japan) and total RNA was immediately isolated. cDNA preparations and real-time quantitative PCR with a TaqMan fluorescent probe for the measurement of ADFP expression were done essentially as previously described (11) . In each experiment, at least two independent real-time quantitative PCR reactions were done to obtain the mean expression values. Obtained signals were normalized by dividing by the mean expression signal of h-actin.
Statistical analysis. The m 2 test, independent samples t test, MannWhitney U test, Wilcoxon signed-rank test, or Kruskal-Wallis H test was used to examine differences between groups depending on the data set. To define the optimal cutoff value of ADFP expression in the real-time quantitative PCR analysis, as well as the tumor size, we applied the receiver operating characteristic method to estimate candidate cutoff point regions. We then searched for the optimal cutoff point for these characteristics, which showed the maximum statistical power by the Kaplan-Meier cancer-specific survival estimation with the log-rank test (Supplementary Figs. S1 and S2). Survival time was defined as the time from nephrectomy or, in cases with recurrence, the time from when the tumor recurrence was discovered until the patient's death or the last time that the patient was known to be alive. Both cancer-specific survival and cancer-free survival curves were estimated by the Kaplan-Meier method, and the resulting curves were compared using the log-rank test. Univariate and multivariate analyses were done using the Cox regression models. In multivariate analysis, the Cox proportional hazards model was used to examine the simultaneous effects of several variables on patients' outcomes. All data were consistent with the assumptions of Cox proportional modeling. All statistical analyses were done with SPSS software (SPSS, Inc., Chicago, IL). All statistical tests were two sided with P < 0.05 considered as statistically significant.
Results
ADFP expression levels, clinicopathologic variables, and VHL alteration in clear cell RCC. We examined a total of 432 primary sporadic clear cell RCCs as well as 49 corresponding normal kidney samples for ADFP expression levels using realtime quantitative PCR (the detailed clinicopathologic characteristics are listed in Supplementary Table S1 ). The median signal values detected in the real-time quantitative PCR for primary tumors (n = 432) and normal kidney tissue samples (n = 49) were 1.319 and 0.429, respectively. Therefore, as previously observed (11) , ADFP was clearly up-regulated in clear cell RCCs compared with normal kidney tissues (P = 9.37eÀ16, MannWhitney U test).
We next explored possible correlations between ADFP expression levels and various clinicopathologic characteristics in clear cell RCC cases. The ADFP expression level was significantly higher in cases without a symptomatic presentation, as well as in lower-stage or lower-grade tumors, compared with normal kidney tissue ( Table 1) . ADFP was originally characterized as one of the differentiation markers for adipocytes (12) . Among the 432 primary RCCs studied, 40 (9.3%) tumors contained a spindle/pleomorphic histologic A, the ADFP expressions in each category are shown by the dot plot as well as by the box-whisker plot.The box depicts the borders of 25% and 75% quartiles; horizontal bar, median value.Whiskers, ranges. Nk, normal kidney tissue; Sp/Pl, spindle/pleomorphic. B, the ADFP expression signal values in the pairing of the primary tumor and its metastasis. Prt, primary tumor; Met, metastasis. P values were calculated using Wilcoxon signed-rank test.
component, which is considered to be an undifferentiated or dedifferentiated manifestation of conventional RCC (5, 6, 22) . When we fractionated these 40 tumors and measured their ADFP levels, we found that the ADFP expression was significantly lower compared with that of conventional clear cell subtype RCCs with G1 to G3 grading (Fig. 1A) . In addition, among conventional clear cell RCCs, there was a tendency for the level of ADFP expression to decrease with increasing tumor grade ( Fig. 1A ; Table 2 ). These correlations suggested that in clear cell RCC, ADFP levels are representative of the tumor differentiation status. Among the 432 clear cell RCC cases, we previously measured the VHL gene alteration status in 220 cases, and these earlier results showed that 116 (53%) cases had a somatic intragenic mutation or hypermethylation of the VHL gene (8, 23) . ADFP expression levels were clearly higher in VHL alteration -positive clear cell RCCs compared with VHL alteration -negative ones (P = 0.010, Mann-Whitney U test; Table 1 ). ADFP expression did not correlate with the other clinicopathologic variables (i.e., patient age, sex, tumor size, and tumor vascular invasion status; Table 1 ).
Comparison of the ADFP expression levels in the primary tumors and metastatic lesions. Among our RCC cases, a total of 18 metastatic lesions (6 lung, 4 bone, 4 contralateral kidney, 2 skin, 1 adrenal, and 1 brain metastasis) in 14 patients were surgically resected and available for the real-time quantitative PCR analyses together with the primary RCCs. When the ADFP expression levels were compared between the primary tumors and their paired metastases, the metastatic lesions showed a clearly lower ADFP expression than did the primary tumors overall (P = 0.001, Wilcoxon signed-rank test; Fig. 1B ). It is notable that the ADFP expression values for all 18 metastases were appreciably low (median, 0.418; range, 0.049-1.369) and comparable with those of primary tumors with a spindle/ pleomorphic component (Fig. 1A and B) . Further investigation of the paired samples suggested that there may be two classes categorized according to the ADFP expression patterns: one class containing 8 (44%) pairings in which the primary tumor expressed a relatively high level of ADFP and the metastasis showed down-regulation of ADFP, and another class comprising the remaining 10 (56%) pairings in which the ADFP expression was fairly low both in the primary tumors and the metastases (Fig. 1B) .
Survival test models in the split-sample method. We next explored the association between ADFP expression levels and the survival of patients with clear cell RCC. For this purpose, we applied the split-sample method (i.e., a training-test set approach) to validate the survival test (24) . We divided the patients into two groups: the preliminary training set consisting of 182 patients treated in the earlier period (March 1986-October 1994) and the validation test set group consisting of the remaining 250 patients who were treated in the later period (November 1994-June 2004). The optimal cutoff value for ADFP expression in the training set group was then determined to be 0.910. Based on this cutoff, 116 of the 182 (64%) clear cell RCCs, of which the ADFP expression levels were z0.910, were designated high expression tumors, and the remaining 66 (36%) tumors, of which the ADFP expression was <0.910, were designated low expression tumors. Using the same method, the tumor size was classified into three categories: V4.5, 4.6 to 9.4, and 9.5 cm ( Supplementary Figs.   S1 and S2) . We then applied these cutoff values in the following survival analyses.
ADFP expression and survival of patients with clear cell RCC. We examined the ADFP expression levels and survival rates of patients with clear cell RCC. In the univariate analyses, ADFP expression levels were strongly associated with cancerspecific survival for the training set, test set, and all-patient cases ( Fig. 2A; Supplementary Table S2 ). The patients with tumors that showed high ADFP expression had significantly better cancer-specific survival than the patients with tumors that showed low ADFP expression. On the other hand, in cancerfree survival tests, the statistical significance of ADFP was detected for the test set and the all-patient cohort but not for the training set group (Fig. 2B; Supplementary Table S3 ). In the present univariate analyses with the split-sample model, as in the previous study, clinicopathologic characteristics such as symptomatic presentation, tumor size, tumor stage, grading, and microvascular invasion status showed a strong association with both cancer-specific survival and cancer-free survival rates (except for the tumor stage in the training set/cancer-free survival; Supplementary Tables S1 and S2).
Next, we used multivariate analysis to determine whether the association between ADFP expression and patient survival was independent of other outcome predictors. The Cox proportional hazards model for all characteristics showed that the ADFP expression remained a statistically significant independent predictor for the test set and the all-patient cohort in cancer-specific survival tests (Table 3) . On the other hand, for cancer-free survival tests, a significant ADFP expression was not detected in any of the patient cohorts tested (Table 4) .
ADFP is a survival predictor for advanced metastatic clear cell RCC. Finally, we studied the effect of ADFP expression on the survival time of advanced metastatic RCC patients with apparent tumor burdens. A total of 93 patients with stage IV disease received a palliative surgery, and 71 patients who had developed tumor recurrence were combined and enrolled for the analysis. In the univariate analyses, we detected significant survival differences between the ADFP high and low expression groups for the training set, test set, and all-patient cases (Fig.  2C) . In further multivariate analysis models examining five variables (patient age, sex, tumor grade, vascular invasion, and ADFP expression), ADFP expression was still found to be an independent predictor of survival time for all three patient cohorts (Table 5 ).
Discussion
We evaluated ADFP expression, a potential prognostic factor, in a relatively large cohort of patients who suffered from clear cell RCC and who had been followed up for a substantial period of time; the cohort contained all tumor stages. We measured ADFP expression levels by means of the TaqManbased real-time quantitative PCR assay, which is a simple, rapid, and sensitive transcription detection method that is applicable to current clinical practice (25, 26) . We applied the Cox regression model combined with the split-sample method to survival tests as a validation method because the study was basically designed in a retrospective manner (24, 27) . We found that the RCC patients with high expressions of ADFP showed better outcomes than those with low expressions of ADFP in both cancer-free survival and cancer-specific survival tests. Furthermore, this validation method enabled us to show that ADFP expression is an independent predictor of cancerspecific survival in a patient cohort containing all tumor stages, as well as for a cohort of patients with advanced metastases (i.e., stage IV cases or tumor recurrent cases), and is of special value because only a few informative biomolecular markers have been identified for patients with such tumor burdens (3). The current study supports our previous finding that ADFP was up-regulated both at the transcriptional and protein levels in cancerous cells of clear cell RCC, whereas ADFP protein existed at levels almost undetectable by immunohistochemistry in normal kidney tissues, including proximal tubular epithelial cells, which are considered to be precursor cells for clear cell subtype RCC (11, 22) . We confirmed again that the ADFP message detected by real-time quantitative PCR is clearly high in clear cell RCCs compared with normal kidney tissue samples. Moreover, we showed that among conventional clear cell subtype RCCs, the ADFP expression levels tended to decrease with increasing grade of tumor, and that, consequently, these levels were significantly low in tumors with a spindle/ pleomorphic component, the dedifferentiated histology of which indicates an aggressive and highly metastatic potential (5, 6, 22, 28) .
In our previous study, ADFP protein was mainly stained in clear cell RCC cells by immunohistochemistry, and the ADFP expression levels quantified by immunohistochemistry and real-time quantitative PCR assay in selected tumors (n = 28) were well correlated (q = 0.601, Spearman's rank correlation test; ref. 11). 3 We therefore believe that the ADFP mRNAs detected by the real-time quantitative PCR assay are primarily a reflection of the expression in tumor cells, although we used grossly dissected tissue samples. Alternatively, the immunohistochemistry-based ADFP semiquantification would also be useful for predicting the survival of patients with clear cell RCC.
It is now widely believed that multiple genetic changes accumulate during the sequential processes of cancer transformation, tumor progression, and the acquisition of aggressive and metastatic potential (29, 30) . Our findings suggested that after ADFP is transcriptionally activated in a relatively early step, it is gradually down-regulated during the later dedifferentiation processes in the tumorigenesis of clear cell RCC. We observed that the VHL alteration -positive clear cell RCCs expressed higher levels of ADFP compared with the VHL alteration -negative ones. The inactivation of the VHL tumor suppressor is a hallmark of clear cell RCC and is considered to be the initial step in the multistage tumorigenic model (4, 9, 10). The ADFP transcription is known to be mediated by HIF (18) . HIF-a is one of the critical targets for ubiquitin-dependent proteasome degradation by the VHL-ElonginBC-Cul2/Rbx1 ubiquitin ligase complex in clear cell RCC (4, 9, 10). We had previously examined gene expression profiles both in pVHL-deficient and wild-type pVHL-positive RCC cells of various cell densities by means of the in vitro VHL introduction model (31) . We observed that the transcription of ADFP was repressed by the introduction of wild-type pVHL. Its repression levels were comparable with those of vascular endothelial growth factor or glucose transporter-1. 3 These are well characterized as major targets for the VHL/HIF signaling cascade in RCC cells (32) . Taken together, these findings strongly suggest that the up-regulation of ADFP is caused by the disruption of the VHL/HIF pathway in clear cell RCC.
Very recently, carbonic anhydrase IX (CA9) and hypoxiainducible protein 2 (HIG2) have been identified as potential diagnostic and prognostic biomarkers for clear cell RCC (33, 34) . It is notable that, like ADFP, both molecules are located in the region downstream of the VHL/HIF signaling (34, 35) . Moreover, CA9 and HIG2 are expected to have potential applications for therapeutic interventions (34, 36) . We previously showed that VHL-mutated clear cell RCCs show better survival rates than VHL-mutation negative RCCs (37) . Therefore, these newly characterized prognostic biomarkers are likely to reflect, in part, the VHL mutational status. Conversely, other molecules located downstream of the VHL/HIF cascade could be potential biomarkers and/or even novel therapeutic targets for clear cell RCC.
It is also known that ADFP is transcriptionally activated by the peroxisome proliferator-activated receptor (PPAR) -mediated pathway (38) . The PPAR family consists of three isotypes, PPARa, PPARh/y, and PPARg. These isotypes belong to a subfamily of nuclear receptors that heterodimerize with retinoid X receptors and regulate the transcription of various target genes, including ADFP. PPARs play fundamental roles in regulating energy homeostasis, including lipid and glucose metabolisms (39) . Moreover, PPARs, the g isoform in particular, are involved in the modulation of the growth of cancerous cells in a wide range of organs, such as in carcinomas of the colon, lung, thyroid, bladder, pancreas, and kidney (40 -42) . PPARg is known to be highly expressed in RCC (43) . Moreover, treatment of RCC cells with ligands of PPARg has been shown to induce growth inhibition and apoptosis (43, 44) . In addition to VHL/HIF, the PPARg-mediated signaling cascade and/or its activated status may play a role in modulating the ADFP expression status in clear cell RCC.
In the present study, we found that the ADFP expression levels in the metastases were very low and were comparable with those in the spindle/pleomorphic RCC. Interestingly, in cases where the primary tumor showed a relatively high level of ADFP, ADFP was down-regulated in its metastasis, whereas in other cases, the levels of ADFP were fairly low in both the primary tumor and its metastasis. The classic paradigm of metastasis proposes that rare subpopulations within primary tumors acquire metastatic capability via sequential mutations, suggesting that metastases are genetically dissimilar from their primary tumors (30, 45) . On the other hand, more recent data suggest that primary tumors have already acquired genetic changes capable of aggressive and metastatic potential. Thus, the molecular genetic profiles of both the primary tumor and its metastatic lesions have been shown to be quite similar (46, 47) . The ADFP expression signatures between the primary tumor and its metastasis suggest that both metastatic patterns may exist in clear cell RCC, although the number of analyzed samples was limited. In summary, we showed that ADFP is a novel prognostic expression signature for clear cell RCC. The measurement of ADFP expression should serve as a useful index of cancerspecific survival rates of patients with all tumor stages as well as those with advanced metastases. In addition, the elucidation of the signal cascades and/or molecules modulating ADFP should help to advance our understanding of the biology of clear cell RCC. 
